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 ABSTRACT 
Gemcitabine is a nucleoside analogue commonly used in cancer therapy but with limited efficacy 
due to a high susceptibility to cancer cell resistance. The addition of a phosphoramidate motif to 
the gemcitabine can protect it against many of the key cancer resistance mechanisms. We have 
synthesized a series of gemcitabine phosphoramidate prodrugs and screened for cytostatic activity 
in a range of different tumor cell lines. Among the synthesized compounds, one in particular 
(NUC-1031, 6f) was shown to be potent in vitro.  Importantly, compared with gemcitabine, 6f 
activation was significantly less dependent on deoxycytidine kinase and on nucleoside 
transporters, and it was resistant to cytidine deaminase-mediated degradation. Moreover, 6f 
showed a significant reduction in tumor volumes in vivo in pancreatic cancer xenografts. The 
ProTide 6f is now in clinical development with encouraging efficacy signals in a Phase I/II study, 
which strongly supports the ProTide approach to generate promising new anti-cancer agents.  
  
INTRODUCTION 
Nucleoside analogues and nucleobases constitute a major class of chemotherapeutic agents and 
are widely used for the treatment of patients with cancer. This group of agents, known as anti-
metabolites, includes a variety of pyrimidine and purine nucleoside derivatives with cytotoxic 
activity in both hematological and solid tumors. Gemcitabine
1
 (2,2- difluoro-2-deoxycytidine) 
is a pyrimidine nucleoside analogue, shown to be active against several solid tumor types.
2  
Following FDA approval in 1996, gemcitabine has become the standard of care for the treatment 
of pancreatic cancer.
3
  More recently, the compound has also gained approval for treating non-
small cell lung, ovarian, bladder, and breast cancer.
4   
 At a molecular level, the mechanisms underpinning the anti-cancer effect of gemcitabine 
rely on the sequential conversion of the compound into the monophosphate (dFdCMP), 
diphosphate (dFdCDP) and then triphosphate (dFdCTP) forms. Gemcitabine triphosphate 
replaces deoxycytidine during DNA replication, which leads to cell arrest.
5
 Failure to repair the 
DNA subsequently triggers apoptosis and blocks tumor growth. In addition, several self-
potentiating mechanisms have been reported, such as inhibition of DNA synthesis by dFdCTP 
and of ribonucleotide reductase (RNR) by dFdCDP.
6
 Notably all of these mechanisms require 
phosphorylation of gemcitabine at least to the monophosphate level.  
 Both innate and acquired resistance to nucleoside analogues (such as gemcitabine, 5-
fluorouracil, cytarabine and fludarabine) is a common problem in the treatment of cancer and is 
regarded as a key driver of poor patient survival outcomes. Gemcitabine, like all nucleoside 
analogues, faces numerous inherent and acquired cancer resistance mechanisms that dramatically 
limit its effectiveness. These include: (i) poor conversion of the drug into the active dFdCDP and 
dFdCTP forms; (ii) rapid degradation into toxic byproducts; and (iii) limited uptake by cancer 
cells. These effects are due to: (i) down-regulation of the key initial phosphorylating enzyme 
deoxycytidine kinase (dCK)
7
 required to convert gemcitabine into the monophosphate form, 
considered the key rate-limiting step in its activation process
8
; (ii) expression of the key 
deactivating enzyme  cytidine deaminase
9
;
 
and (iii) deficiency of nucleoside transporter
10
 
proteins. In addition, increased expression and/or activity of cytidine deaminase (CDA) increases 
the degradation of gemcitabine into the toxic metabolite 2,2-difluoro-2-deoxyuridine (dFdU).9 
Because of these processes, single agent gemcitabine has limited activity in cancer treatment, 
with response rates of less than 10% in pancreatic cancer.
11
 
 Various strategies to improve the treatment efficiency of gemcitabine have been 
developed, including the chemical modifications and functionalization of its 4-(N) and 5-sites 
(reviewed in Moysan et al.).
12
 In 2009, Bender et al. reported an orally active prodrug of 
gemcitabine, LY2334737 which is significantly less prone to degradation by CDA due to a 
valproic acid linkage at the 4-(N)-position.
13
 Based on in vivo data in the HCT-116 human colon 
xenograft, LY2334737 has been further developed and advanced into Phase I clinical studies, 
either alone or in combination therapy with other agents.
14 
As an alternative approach, CP-4126 
was developed
15
 to enhance the cellular uptake of gemcitabine, by attaching a fatty acid chain to 
the ribose 5-position, but this failed to show superiority over gemcitabine in clinical trials.16 
While these strategies  may offer theoretical benefits, they only address one or two of the three 
known resistance mechanisms associated with gemcitabine. Notably, these approaches do not 
overcome the inability of the resistant cancer cell to activate gemcitabine through 
phosphorylation. This obligatory first-phosphorylation step is likely to limit the therapeutic 
effectiveness of these prodrugs, as is established for the parent nucleoside analogue. Therefore, a 
different approach, utilizing a pre-activated monophosphate form of these nucleoside analogues 
has emerged as a therapeutic approach.
17
  
 A major strategy currently applied in the modulation of several antiviral nucleoside 
analogues is the ProTide technology developed in 1995 by our laboratories.
18 
This method is 
designed to overcome the key resistance mechanisms associated with nucleoside analogues in 
general. Bearing one phosphate group protected with biolabile groups (termed the 
phosphoramidate motif), the ProTides are pre-activated, thereby bypassing the initial rate-
limiting step of kinase phosphorylation into the monophosphate form. Importantly, the cellular 
 uptake of these compounds is independent of nucleoside transporters and their resistance to 
deactivation by deaminases and other enzymes is superior to nucleoside analogues.
19
 The 
addition of the phosphoramidate motif will also change the pharmacokinetic/dynamic properties, 
that may be favorable for therapy. Overcoming cancer resistance mechanisms should lead to 
significant clinical benefits.  
 In our laboratory we have extensively investigated the phosphoramidate ProTide 
approach and successfully applied this technology to many active antiviral agents such as d4T,
20
 
abacavir,
21
 and various anti-hepatitis C virus agents.
22
  Similarly, we generated ProTides based 
on several anti-cancer nucleosides such as cladribine,
23
 clofarabine
24
 and recently to 5-fluoro-2-
deoxyuridine (FUDR),
25
 with very encouraging results. Here we report the application of the 
ProTide technology to the cornerstone of pancreatic cancer treatment, gemcitabine, and the 
screening process that has identified a novel lead candidate, now in clinical development. 
The potency of the compounds varies with the individual components (aryl, ester and amino 
acid) of the phosphoramidate moiety and therefore we examined a panel of gemcitabine 
ProTides. Thus, we herein report for the first time in the open literature the design, synthesis, 
anti-tumor evaluation and metabolic studies of a panel of L-alanine-based gemcitabine 
phosphoramidates. NUC-1031 (6f, first patented by us in 2005 as CPF-31
26
) emerged as the 
most promising compound. The compound is currently making progress through the clinical 
development stage and has already shown very encouraging activity against a range of solid 
tumors and a favorable safety profile in a Phase I study.
27
 
 
CHEMISTRY 
The synthesis of gemcitabine ProTides is largely based on phosphorochloridate chemistry and 
requires the preparation of two components: a regioselectively protected gemcitabine on the 3’-
OH group and an aryl aminoacyl phosphorochloridate.  
 First, gemcitabine (1) was selectively protected on the 3-OH group28 in order to favor the 
5-regio-selectivity of the phosphorylation with the aryl aminoacyl phosphorochloridates 
(Scheme 1). Thus, gemcitabine was allowed to react with tert-butyl dicarbonate in 1,4-dioxane 
and water (4:1 v/v) at room temperature for 48h to give the corresponding intermediate (4) with 
a 75% yield after column chromatography.  
 
Scheme 1. Selective protection of gemcitabine (1) 
Reagents and conditions: a) DBOC, Na2CO3, 1,4-dioxane/H2O (4:1 v/v), rt, 48h. 
 
 In parallel, the aryl aminoacyl phosphorochloridates (3), which are key reagents in the 
ProTide methodology, are prepared using two reagents: an esterified amino acid and an aryloxy 
phosphorodichloridate (Scheme 2).
29
 The first reagent, an amino acid ester, if not commercially 
available, can be prepared by esterification of the appropriate amino acid via standard 
esterification methods.
30
 The second reagent is an aryl (phenyl or 1-naphthyl) 
phosphorodichloridate; the phenyl phosphorodichloridate is commercially available, whereas the 
1-naphthyl analogue (2) can be obtained by reacting 1-naphthol with phosphorus oxychloride 
and triethylamine following published procedures.
31
 
 The aryl aminoacyl phosphorochloridates (3) were formed by reaction of phenyl or 1-
naphthyl phosphorodichloridates with appropriate amino acid esters in the presence of 
triethylamine, as outlined in Scheme 2. Chiral amino acid esters generated a pair of 
diastereoisomers at the phosphate center, in about 1:1 ratio, visible by two close peaks in the 
31
P 
NMR spectra. In most cases, the aryl aminoacyl phosphorochloridate (3) syntheses were 
completed within two hours as monitored by 
31
P NMR.  Because of their limited stability, these 
products (3) were then used as crude materials, or after rapid silica gel chromatography, in the 
 ProTide syntheses.  
 
Scheme 2. Synthesis of aryl aminoacyl phosphorochloridates (3a-l) 
Reagents and conditions: a) POCl3, Et3N, dry Et2O, -78 C for 1h then rt for 1h; b) (2) or phenyl 
phosphorodichloridate, Et3N, dry DCM, -78 C, 1-3h. 
 
 Next, each aminoacyl phosphorochloridates (3) were reacted with the 3-protected 
gemcitabine (4) in the presence of tert-butylmagnesium chloride (1.0 M solution in THF) as 
shown in Scheme 3. Overnight reactions at ambient temperature generated crude materials that 
were purified by column chromatography to provide good yields of 3-Boc-protected 
phosphoramidates 5a-l. Finally, the end products 6a-l were obtained through acidic deprotection, 
typically 2-4 hours reaction at 0 C in TFA/DCM (1:1 v/v), followed by basic work-up and 
column purification on silica gel. As a result of the phosphate chirality, ProTides 6a-l were 
isolated as diastereoisomeric mixtures, evidenced by 
31
P NMR, HPLC (two peaks), 
1
H NMR, 
and 
13
C NMR (with splitting of many nucleoside signals). Extensive Structure/Activity 
Relationship (SAR) studies,
32
 and prior work suggested that the L-alanine phosphoramidates 
were the most potent gemcitabine ProTides.
26
 Thus, we further explored this ProTide family 
bearing the L-alanine residue by altering the aryl and ester moieties. This led us to prepare both 
series of phenyl and 1-naphthyl L-alanine gemcitabine ProTides with branched (isopropyl, 
neopentyl), linear (pentyl, hexyl), cyclic (cyclopentyl, cyclohexyl) and benzyl ester motifs.  
 
Scheme 3. Preparation of gemcitabine ProTides (5a-l, 6a-l) under coupling conditions 
Reagents and conditions: a) (ArO)(R
2
OC(O)CR
1
NH)P(O)Cl (3a-l), tert-BuMgCl, THF, rt, 16h; 
b) TFA/DCM (1:1 v/v), 0 C, 2-4h. 
 
BIOLOGICAL ACTIVITY IN VITRO 
Nucleoside analogues face numerous inherent and acquired cancer resistance mechanisms that 
can dramatically limit their effectiveness. ProTides are specifically designed to overcome these 
key cancer resistance pathways and thereby achieve a superior anti-neoplastic effect. Over the 
years, our laboratory has created a large library of over 3,500 ProTides and built considerable 
know-how as to structure/activity relationships through multiple rounds of pharmacomodulation 
and functional tests. By applying the ProTide chemistry to gemcitabine, more than 80 different 
compounds were generated with various natural amino acids (data not published). Early 
chemical and biological screens during the development of this ProTide family, led to the 
conclusion that L-alanine-based molecules best enhanced functional activity. This is in keeping 
with previous experience. Several L-alanine phosphoramidate compounds were synthesized, 
with numerous variations on the aryl and ester groups, and these were screened in vitro for 
 cytotoxic activity against a range of cancer cell lines. Of these, six compounds showed activity 
comparable to or better than gemcitabine and the results are summarised in Table 1. ProTides 
showed a broad spectrum of activity levels around the gemcitabine IC50 reference value, which 
was used as a positive control. Notably, within the series of compounds tested, ProTides 6f, 6i 
and 6k demonstrated better (2 to 4 fold increase) potency than gemcitabine in pancreatic 
(MiaPaCa-2, BxPC-3) cell lines.  Because gemcitabine is the cornerstone of pancreatic cancer 
treatment, these data were particularly encouraging.  
 
Table 1. IC50 (M) values of selected prodrug derivatives against four cancer cell lines 
 
 
a
 IC50 (50% Inhibitory Concentration) is the compound concentration required to inhibit tumor 
cell proliferation by 50%. 
b
 DMG is dimethylglycine. Data shown are the mean of at least two 
independent experiments. 
  
 To exert their anti-cancer activity the ProTides should be metabolised to release the 
monophosphate form, which will then generate the active compounds, gemcitabine di- and tri-
phosphate. The proposed intracellular activation route of the ProTides has been described
33
 for 
other ProTide families, such as the FUDR ProTides, and is depicted in Scheme 4. The 
hypothesised metabolic route would begin with the hydrolysis of the ProTide ester (i), mediated 
by a carboxyesterase-type enzyme to form the intermediate (A). This step is followed by a 
spontaneous cyclisation (ii) displacing the aryl moiety via an internal nucleophilic attack of the 
carboxylate residue on the phosphorus centre to yield (B). In a third step (iii) the unstable cyclic 
mixed anhydride would be hydrolysed to release the intermediate (C). The final step (iv) would 
then involve a phosphoramidase-type enzyme, which would cleave off the amino acid to 
generate the corresponding monophosphate (D).  
 
Scheme 4. Proposed activation pathway of gemcitabine ProTide 6f. 
 
 To support the proposed activation pathway ProTide 6f was incubated with 
carboxypeptidase Y. This assay
34
 was designed to verify whether an enzymatic cleavage of the 
ester motif would be sufficient to trigger the first steps of the activation route and generate the 
intermediate (C). Compound 6f was dissolved in acetone-d6 in the presence of Trizma buffer (pH 
7.6) and treated with carboxypeptidase Y to monitor the metabolic conversion of the ProTide by 
31
P NMR spectroscopy over time (Figure 1). Two peaks at  3.64; 3.37 ppm in the blank 
spectrum recorded at 25 C correspond to the diastereoisomers of the parent compound 6f. 
Within 10 minutes of incubation with carboxypeptidase Y, a single peak at 4.35 ppm started 
appearing, consistent with the chemical shift of the metabolite (A) lacking the ester moiety. A 
 further processing of the intermediate (A) led to the formation of a third peak  6.80 ppm after 
10 minutes, which is consistent with the single chemical shift expected for the achiral 
intermediate (C). The peak increased over time and persisted, suggesting the accumulation of a 
stable product. Therefore, the spectra recorded during the enzymatic reaction suggest that within 
12 hours of assay 6f was almost fully converted into the metabolite (C) via the intermediate (A) 
and strongly support the proposed pathway as the actual ProTide activation route. 
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Figure 1. 
31
P NMR spectra of ProTide 6f over time after carboxypeptidase Y digestion showing 
the signals of metabolites. 
 
 The optimal metabolism of these ProTides depends on their chemical stability. Upon 
administration, the circulating ProTides are exposed to challenging conditions, such as catalytic 
enzymes in the liver and should resist long enough to enter tumor cells before being degraded. 
Conversely, ProTides unaffected by enzymatic digestion might not be efficiently converted into 
active compounds inside the cancer cells. To further select the lead candidates with suitable 
chemical stability, six ProTides were incubated with human hepatocytes and liver microsomes. 
The half-lifes and the percentage of ProTide remaining after one hour were measured and are 
summarised in Table 2. In the human hepatocyte extracts the half-life of the six compounds 
varied from 79 minutes for 6k, up to >1000 minutes for 6d. The selection criteria included 
identifying a compound with a mid range half-life in human hepatocytes. Importantly, 
compounds 6f and 6j met this criterion. Next, the stability of ProTides was further investigated 
using liver microsomes. After one hour incubation 18% of 6f remained detectable, while 6j had 
entirely been processed. These results, together with the cytotoxic data shown earlier, pointed to 
ProTide 6f (L-Ala-OBn phenyl) as the lead candidate for further analyses. 
 
Table 2. Metabolic stability of ProTides incubated with human hepatocytes and liver 
microsomes. 
 
 
 
 
 
 
 
  
 Next, the stability of the lead compound, ProTide 6f in the presence of human serum was 
investigated using in situ 
31
P NMR (Figure 2). The ProTide was dissolved in deuterated solvent 
and scanned at 37 C at regular intervals over 13 hours to monitor the formation of metabolites. 
The resolution of the recordings was improved using the Lorentz-Gauss deconvolution method. 
The spectra initially displayed a single peak due to human serum at  2.42 ppm and a broad peak 
at  4.15 ppm, which can be assigned to the ProTide 6f. After 5 h 30 minutes incubation, a third 
signal appeared at  7.27 ppm consistent with the chemical shift expected for metabolite C 
 
 (Scheme 4). The reaction mixture contained 59% of the original compound 6f after 13 hours 
together with 41% of the putative intermediate C. This suggests that in the presence of human 
serum the ProTide 6f was converted to the metabolite C with an estimated half-life of over 
14 hours. Also, these results indicate that the stability of the compound should be suitable for 
clinical studies.  
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Figure 2. Deconvoluted 
31
P NMR spectra of ProTide 6f over time after incubation with human 
serum showing the signals of metabolites. 
 
 The ProTides are specifically designed to overcome the key drug resistance mechanisms 
associated with nucleoside analogue treatments against cancer. At the cellular level, gemcitabine 
resistance in particular is dependent on three parameters: (i) the down-regulation of 
deoxycytidine kinase, necessary for the activation into the phosphorylated moiety; (ii) the 
reduced expression of nucleoside transporters in particular hENT1 required for uptake by cancer 
cells and  (iii) the up-regulation of catalytic enzymes especially cytidine deaminase that degrades 
gemcitabine. Thus, the lead ProTide 6f was evaluated for its ability to bypass these three key 
resistance mechanisms. Because the ProTide is synthesised as a masked monophosphate it is 
expected to bypass the dCK-dependent phosphorylation event for its activation, which is the 
rate-limiting step to generate the di- and tri-phosphate active moieties. To test this hypothesis, 
the cytotoxicity of 6f and gemcitabine on RT112 cancer cells was measured in the presence of a 
substrate for the dCK enzyme, 2’-deoxycytidine (Figure 3A). This compound was shown to 
compete with gemcitabine for dCK activity
7b,9b
, which mimics a down-regulation of the enzyme. 
In the presence of deoxycytidine the gemcitabine concentration required to block cell 
proliferation, EC50 increased 75-fold from 1.4nM to 104.9nM, as determined in the colorimetric 
MTT assay measuring the number of viable cells in culture. By contrast, 6f was more cytotoxic 
than gemcitabine (i.e. 6f: EC50 lower than gemcitabine EC50) and its activity was not 
significantly affected by deoxycytidine (6f: EC50 = 0.7nM in the presence of deoxycytidine as 
opposed to 0.2nM without deoxycytidine). This result indicates that 6f can bypass dCK-mediated 
monophosphorylation step to block tumor cell growth.  
 Next, we explored whether the ProTide could overcome the requirement for nucleoside 
analogue transporters to enter the cancer cells. In a similar assay, the growth inhibition effect of 
gemcitabine and 6f was studied on PANC1 pancreatic cancer cells in the presence of an inhibitor 
of nucleoside transport, dipyridamole (Figure 3B). This inhibitor blocks hENT1 transporter 
activity to resemble cancers where the transporters responsible for nucleoside uptake are down-
regulated. When gemcitabine was incubated with dipyridamole, its cytotoxic activity was 
markedly reduced, with the EC50 significantly increasing from 611M to >2000M. In contrast, 
the ProTide, which had a baseline activity ~3 fold superior to gemcitabine (190M compared to 
611M for gemcitabine), maintained a strong cytotoxic level in the presence of the inhibitor 
(EC50 = 162M). These data suggest that 6f is not reliant on the nucleoside transporter hENT1 to 
enter the cells and exert its anti-cancer effect.  
 Cytidine deaminase found in the serum and inside the cells can break down gemcitabine 
and thereby limit its activity. Expression of this enzyme is thought to play a key role in the 
resistance to the drug
35
. Unprotected hydroxyl groups at positions 3 and 5 of the nucleoside 
 analogue were shown to be necessary for the cleavage to occur.
36
 In addition, the amino acid 
ester prodrugs of gemcitabine have been reported previously to be resistant to deamination by 
cytidine deaminase in vitro.
37
  
Because 6f bears a phosphoramidate moiety on the 5-carbon of the ribose it was predicted to 
resist deamination. To assess their resistance to enzymatic breakdown, the ProTide and 
gemcitabine were incubated with cytidine deaminase and monitored by UV absorption 
spectroscopy at wavelengths between 220 to 350 nm (Figure 3C). The absorbance of 
gemcitabine shifted from 267 nm to 257 nm within the first 2 minutes of the UV assay, 
suggesting breakdown of gemcitabine and conversion to the corresponding dFdU toxic 
metabolite. The spectrum of 6f remained unchanged (Abs 267 nm) at 30 minutes and 
demonstrates that the ProTide is resistant to deaminase breakdown. Because 6f is less susceptible 
to degradation, it is anticipated that it should release less harmful deaminated catabolite, dFdU, 
and have a more favorable safety profile in patients. Together, the cytotoxicity and absorbance 
data support a model where the ProTide 6f is able to overcome the three key resistance 
mechanisms associated gemcitabine. 
A       B 
 
Bladder cancer cell line (RT112); 100µM deoxycytidine. Pancreatic cancer cell line (PANC1), 100µM dipyridamole 
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Figure 3. The ProTide 6f overcomes the key cancer resistance mechanisms associated with 
gemcitabine in vitro. (A) Effect of deoxycytidine-mediated dCK inhibition on gemcitabine 
(GEM) and 6f cytotoxicity in RT112 cells. (B) Effect of dipyridamole-mediated nucleoside 
transport inhibition on gemcitabine (GEM) and 6f cytotoxicity in PANC1 cells. (C) and (D) 
Absorbance spectra of gemcitabine and ProTide 6f exposed to cytidine deaminase over 30 
minutes. 
 
 Gemcitabine is a prodrug, which requires further processing into the di- and tri-phosphate 
active moieties (dFdCDP and dFdCTP, respectively) to block cancer cell growth. The 
triphosphate form is considered the main driver of the anti-cancer effect, directly interfering with 
DNA replication, while the diphosphate derivative is thought to further potentiate the activity.
5
 
 To test whether 6f cytotoxic activity correlates with high levels of intracellular dFdCTP, the 
ProTide was tested in a cell growth assay for 24 hours before measuring the intracellular 
dFdCTP levels (Figure 4). The cells were again exposed to different inhibitors to recreate the 
drug resistance conditions associated with nucleoside analogue treatment (i.e. dCK kinase and 
hENT1 transporter down-regulation). As expected, when the pancreatic cancer cells (BxPC-3 
and MiaPaCa-2) were exposed to gemcitabine, the dFdCTP levels were significantly decreased 
upon 2T2D and NBTI treatments (Figure 4A and 4B, compare RED and PINK for both cell 
lines). In contrast, the ProTide (in dark and light blue) maintained steady levels of the 
triphosphate derivative even in the presence of the inhibitors. These results demonstrate the 
capacity of 6f to bypass the requirement for dCK-mediated activation and hENT1-dependent 
uptake to generate high concentrations of intracellular dFdCTP. Together, these analyses along 
with the cytotoxicity results strongly suggest that the ProTide 6f is efficiently metabolised into 
the active anti-cancer moiety, overcoming the key cancer resistance mechanisms associated with 
gemcitabine and blocking tumor cell growth. 
A)
 
Figure 4. The ProTide 6f generates high intracellular levels of the active moiety bypassing key 
drug resistance mechanisms in vitro. (A) Intracellular levels of dFdCTP (gemcitabine 
triphosphate) in pancreatic cell lines treated with gemcitabine (red and pink) or 6f (dark and light 
blue) in the presence (pink and light blue) or absence (red and dark blue) of the kinase dCK 
inhibitor, 2T2D. (B) Intracellular levels of dFdCTP in pancreatic cell lines treated with 
gemcitabine (red and pink) or 6f (dark and light blue) in the presence (pink and light blue) or 
absence (red and dark blue) of the hENT1 (nucleoside transporter) inhibitor, NBTI.  
 
 The data gathered in vitro prompted us to examine whether the ProTide 6f would also 
have a strong anti-cancer activity in vivo against well-established mouse models with human 
tumor xenografts. First, because the ProTide had previously been shown to undergo rapid 
degradation in rodents due to blood circulating esterases, we examined 6f stability in rat serum 
and compared it with dogs as a non-rodent specie reference (Figure 5A). As expected, when the 
ProTide was incubated with rat serum and monitored by 
31
P NMR over time, the spectra 
revealed the complete conversion of 6f to the achiral metabolite C after 6.5 minutes whereas the 
compound was still stable after 14 hours in dog serum (>80% 6f; 20% metabolite C). The 
estimated half-life of ProTide 6f in rat serum was <5 minutes but exceeded 100 hours in dog 
serum. These analyses of ProTide 6f and metabolite C confirmed the prior findings that rodent 
models are likely to reduce the advantages seen from the ProTides over the parent nucleoside 
analogue.  
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Figure 5 (A) Metabolic stability of 6f incubated with rat and dog serum. (B) Mean body weight 
change (%) of MiaPaCa-2 bearing nude mice following administration of vehicle (n=8), 
gemcitabine (n=8) and 6f (0.19 mmol/kg, 2x/week; n=7). (C) Anti-tumor effect of gemcitabine 
and 6f against MiaPaCa-2 pancreatic xenograft tumors in nude mice. (D) Mean body weight 
change (%) of BxPC-3 bearing nude mice following administration of vehicle (n=8), 
gemcitabine (n=8) and 6f (0.19 mmol/kg, 2x/week; n=7). (E) Anti-tumor effect of gemcitabine 
and 6f against BxPC-3 pancreatic xenograft tumors in nude mice. 
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 To determine the effect of 6f on tumor growth, nude mouse xenograft models of MiaPaCa-2 
human pancreatic cancers were administrated with equimolar doses of gemcitabine, 6f and 
vehicle. The body weight was also recorded to assess the animal’s tolerability of the compound. 
Over the course of the study, the observed change in body weight for the mice treated with 6f 
was less than 4%, and similar to the gemcitabine treated mice (Figure 5B). After the treatment 
stopped, the mean body weight of both groups increased, indicating that the weight loss may 
have been due to the compound’s toxicity. When examining 6f and gemcitabine anti-cancer 
activities, both compounds proved effective, with 6f significantly reducing tumor volume 
compared to control (vehicle) (Figure 5C). Importantly, 6f (0.076 mmol/kg) achieved 
significantly greater reduction in tumor volume than gemcitabine on Day 7 after the first 
administration of the compounds. Moreover, tumor growth was inhibited following the first 
administration of the ProTide and continued to decrease until the dosing was stopped. These 
results were further confirmed with a second human pancreatic cancer cell line known to be 
resistant to gemcitabine, BxPC-3 where 6f achieved a significant reduction in tumor growth 
compared to control unlike gemcitabine (Figure 5E). Interestingly, over the treatment period the 
mean body weight change was less in the mice treated with the ProTide than with gemcitabine, 
suggesting that 6f was better tolerated than the nucleoside analogue (Figure 5D). Overall, even in 
rodents, where the ProTide is very unstable, the reported in vivo tolerability and efficacy of the 
lead compound 6f were at least equivalent to or better than gemcitabine. These results are 
particularly encouraging because the ProTides are more stable in other species (i.e. no circulating 
rodent esterases), including humans and this is expected to translate into superior clinical 
efficacy.  
   
 
CONCLUSIONS 
 
Tumor cells have numerous inherent and acquired resistance mechanisms that can render 
conventional chemotherapy with nucleoside analogues less effective. Here we describe the 
successful application of the ProTide technology to generate new anti-cancer agents to overcome 
the key cancer resistance mechanisms associated with nucleoside analogues, and in particular, 
gemcitabine. The compounds synthesised through phosphoramidate chemistry demonstrated 
superior in vitro and in vivo efficacy compared to gemcitabine, even in experimental conditions 
designed to limit gemcitabine activity. By adding a specific phosphoramidate moiety onto the 
gemcitabine backbone, a series of novel and potent antimetabolite agents were created with 
superior efficacy and an improved safety profile, which were able to bypass the key cancer 
resistance mechanisms that limit gemcitabine activity. One ProTide in particular, 6f, showed 
exceptional activity and was selected for clinical studies in patients with advanced cancers. 
 Gemcitabine is a prodrug with limited clinical utility due to its: reliance on deoxycytidine 
kinase expression for activation;
7
 requirement on nucleoside transporters for cellular entry;
10
 and 
susceptibility to degradation by deactivating enzymes such as cytidine deaminase.
9 
In vitro the 
ProTides showed better cytotoxic activity than gemcitabine against a range of tumor cell lines. 
Importantly, the selected lead compound, 6f generated much higher intracellular levels of the 
active moiety, gemcitabine triphosphate, in experimental conditions known to be associated with 
gemcitabine resistance. In vivo, the ProTide demonstrated a significant reduction in tumor size 
against pancreatic xenograft models compared with the gemcitabine treated group, and less 
adverse effects on body weight, indicating a better safety profile. Together these data strongly 
suggest that the ProTides are not reliant on kinases or nucleoside transporters to exert their 
activity inside tumor cells and remain stable in the presence of deaminases. 
 The ProTide NUC-1031 (6f) is currently advancing through Phase I/II clinical studies 
and has already generated strong pharmacokinetic data that confirm significantly higher 
intracellular levels of gemcitabine triphosphate, together with promising early efficacy signals 
and a favorable safety profile.
27
 The phosphoramidate chemistry is potentially a great source of 
new and very effective anti-cancer agents, bringing a considerable array of advanced treatments 
specifically designed to overcome cancer resistance mechanisms that will benefit a greater 
proportion of patients. 
 EXPERIMENTAL SECTION 
Cytostatic Activity Assays. Murine leukemia L1210 and its dCK-deficient congener 
L1210/dCK
-
, and human lymphocyte CEM and its dCK-deficient congener CEM/dCK
-
 were 
seeded at – 50 to 75 x 103 cells/200 µl in the wells of a 96-well microtiter plate that contained a 
variety of drug concentrations. After 48 hours (L1210) or 72 hours (CEM) the cell number was 
determined by counting with a Coulter Counter. The IC50 (50% inhibitory concentration) was 
determined as the drug concentration required to inhibit tumor cell proliferation by 50%. 
Metabolic Stability (Cryopreserved hepatocytes, human) Assay. The assay was 
contracted and performed by Cerep (Seattle, WA, USA Laboratories 15318 N.E 95
th
 Street 
Redmond, WA, 98052, USA) according to the published procedure (Cerep Ref. 1432).
38  
Pooled 
cryopreserved hepatocytes were thawed, washed and re-suspended in Krebs-Heinslet buffer (pH 
7.3). The reaction was initiated by adding the test compound (1 M final concentration) into cell 
suspension and incubated in a final volume of 100 L on a flat-bottom 96-well plate for 0 minute 
and 60 minutes, respectively, at 37 C/ 5%CO2. The reaction was stopped by adding 100 L of 
acetonitrile into the incubation mixture. Samples were then mixed gently and briefly on a plate 
shaker, transferred completely to a 0.8 mL V-bottom 96-well plate, and centrifuged at 2550 xg 
for 15 minutes at room temperature. Each supernatant (150 L) was transferred to a clean cluster 
tube, followed by HPLC-MS/MS analysis on a Thermo Electron triplequadrupole system.  
Metabolic Stability (liver microsomes, human) Assay. The stability assay was contracted and 
carried out by Cerep (Seattle, WA, USA Laboratories 15318 N.E 95
th
 Street Redmond, WA, 
98052, USA) according to the published procedure (Cerep Ref. 0607).
39
 Pooled liver 
microsomes are pre-incubated with NADPH-regenerating system (1 mM NADP, 5 mM G6P, 
and 1U/mL G6PDHase) in phosphate buffer (pH 7.4) containing 3 mM MgCl2 and 1 mM EDTA 
in a 2 mL-block 96-well plate for 10 minutes in a 37 C shaking water-bath. The reaction was 
initiated by adding the test compound (final concentration 0.5 M) and incubated in a final 
volume of 700 L in the 37C shaking water-bath. At 0, 15, 30, 45 and 60 minutes after reaction 
initiation, 100 L of the incubation mixture is transferred to 100 L of acetonitrile/methanol 
(50/50, v/v) in a 0.8 mL V-bottom 96-well plate. Samples are then mixed on a plate shaker for 5 
minutes and centrifuged at 2550 xg for 15 minutes at room temperature. Each supernatant is 
transferred to a clean cluster tube, followed by HPLC-MS/MS analysis on a Thermo Electron 
triplequadrupole system. 
MTS Cell Viability Assay.  The assay was contracted and carried out by WuXi AppTec 
(Shanghai) Co., Ltd. The corresponding cell lines PC-3, T24/83, MiaPaCa-2, A549, H460, Bx-
PC3, A2780, and HT29 were seeded at range of density 0.5 to 100 x 10
3 
cells/well in the wells of 
96-well plate the day before incubation, then incubated for 72 hours with the different 
concentrations of compound tested. Then 50 L of MTS was added and cells were incubated for 
4 h at 37 C.  The data were read and collected by Spectra Max 340 Absorbance Microplate 
Reader.  
Maximum Tolerated Dose (MTD) Assay was contracted and performed by WuXi 
AppTec (Shanghai) Co., Ltd. Balb/c nude mouse (Slac Laboraory Animal Co., Shanghai, China): 
female, six to eight week old were intraperitoneally given compounds 6f (i.p 0.228 mmol/kg, 
132.3 mg/kg, 2x/WK) and 6j (i.p 0.228 mmol/kg, 141.9 mg/kg, 2x/WK) or vehicle for 2 weeks. 
Compounds were dissolved in 40% Captisol solution. (40% Captisol was prepared by 
dissolving 20 mg of Captisol with pure water, and made the final volume 50 mL. The solvent 
was filtered with 0.22 m filter). Mice were monitored daily for body weight change and clinical 
symptoms for 2 weeks. The results were expressed as means  SEM. 
 In vivo xenograft models of MiaPaCa-2 and BxPC-3 Bearing Mice Assay was 
contracted and performed by WuXi AppTec (Shanghai) Co., Ltd. BxPC-3 cell line, MiaPaCa-2 
cell line (ATCC, USA); RPMI 1640 medium (Invitrogen, USA); FBS (Invitrogen, Australia); 
Balb/c nude mouse (Slac Laboratory Animal Co., Shanghai, China): female, six to eight week 
old, 20  2 g; Captisol (CyDex Pharmaceuticlas Inc., USA). BxPC-3 and MiaPaCa-2 cell line 
cultures were performed according to the cell culture protocols of WuXi AppTec Shanghai) Co., 
Ltd. BxPC-3 and MiaPaCa-2 bearing mice were treated with test compounds or control for 3 
 weeks. Tumor volumes (mm
3
) and body weights were measured two times per week during the 
treatment. Behavioral and physical abnormal changes were observed and recorded. Mice 
continued to grow for one week without above treatment. Tumor volumes (mm
3
) and body 
weights were measured two times per week. Behavioral and physical abnormal changes were 
observed and recorded. The results were expressed as means  SEM. Data was compered using 
student’s t-test. Significant differences were considered to exist for those probabilities below 5% 
(p<0.05). 
Carboxypeptidase Y (EC 3.4.16.1) Assay. The experiment was carried out by 
dissolving ProTide 6f (3.0 mg) in acetone-d6 (0.15 mL) followed by addition of 0.30 mL of 
Trizma buffer (pH 7.6). After recording the control 
31
P NMR at 25 C, a previously defrosted 
carboxypeptidase Y (0.1 mg dissolved in 0.15 mL of Trizma) was added to the sample, which 
was then immediately submitted to the 
31
P NMR experiments (at 25 C). The spectra were 
recorded every 7 minutes over 14 hours. 
31
P NMR recorded data were processed and analyzed 
with the Bruker Topspin 2.1 program.  
Stability Assay in Serum. The experiment was carried out by dissolving ProTide 6f (5.0 
mg) in DMSO (0.050 mL) and D2O (0.15 mL). After recording the control 
31
P NMR at 37 C, a 
previously defrosted human, rat or dog serum (0.30 mL) was added to the sample, which was 
next submitted to the 
31
P NMR experiments at 37 C. The spectra were recorded every 30 
minutes over 13 hours. 
31
P NMR recorded data were processed and analyzed with the Bruker 
Topspin 2.1 program. The Lorentz – Gauss deconvolution method was further used to improve a 
visualization of results.  
Cytidine deaminase (CDA) Assay. CDA assays were performed using modified 
procedure.
40
 Stock solution of gemcitabine and ProTide 6f were dissolved in the assay buffer 
(50mM Tris-HCl buffer pH 7.5) to a final concentration of 100µM. Cytidine deaminase (100µg 
in 200µL 20mM Tris-HCl buffer pH 8.0, containing 1mM DTT, 2mM EDTA, 100mM NaCl, 
40% glycerol) was aliquoted for 4 portions and stored at -20 C prior usage. 50µL aliquot of 
cytidine deaminase was added to 150µL of assay buffer. For each assay, 1mL of 100µM of 
gemcitabine and 6f was placed in a 1cm UV cuvet at 25 C, and UV spectrum was recorded over 
the range  220 to 350nm. A portion of enzyme solution (200µL) was added, and spectra were 
recorded in 1 minute intervals for 30 minutes. 
Chemistry. General. Anhydrous solvents were obtained from Aldrich and used 
without further purification. Amino acid esters were purchased from Carbosynth, 
Carboxypeptidase Y, human serum and buffers from Sigma-Aldrich. Cytidine deaminase 
(recombinant human cytidine deaminase, His-tagged expressed in E.coli, in 20mM Tris-HCl 
buffer pH 8.0, containing 1mM DTT, 2mM EDTA, 100mM NaCl, 40% glycerol, concentration 
0.5 mg/ml as determinated by Bradford assay) was purchased from Creative BioMart. All 
reactions were carried out under an argon atmosphere. Reactions were monitored with 
analytical TLC on Silica Gel 60-F254 precoated aluminium plates and visualized under UV 
(254 nm) and/or with 
31
P NMR spectra. Column chromatography was performed on silica gel 
(35–70 M). Proton (1H), carbon (13C), phosphorus (31P) and fluorine (19F) NMR spectra were 
recorded on a Bruker Avance 500 spectrometer at 25 °C. Spectra were auto-calibrated to the 
deuterated solvent peak and all 
13
C NMR and 
31
P NMR were proton-decoupled.  The purity of 
final compounds was verified to be >95% by HPLC analysis using Varian Polaris C18-A (10 
M) as an analytic column with a gradient elution of H2O/MeOH from 100/0 to 0/100 in 40 
min. (method 1), and with a gradient elution of H2O/CH3CN from 100/0 to 0/100 in 35 min. 
(method 2). The HPLC analysis was conducted by Varian Prostar (LC Workstation-Varian 
prostar 335 LC detector).  Low and High resolution mass spectra were performed as a service 
by Cardiff University, using electrospray spectrometry (ESMS). CDA assays were performed 
with Varian Carry 50 Bio UV/Vis spectrophotometer. UPLC-MS/MS Analysis: dFdCTP was 
resolved using an ultra-performance liquid chromatography system (Accela UPLC, Thermo 
Scientific, UK) equipped with Ascentis Express 2.7 µm C18 4.6 × 100 mm HPLC column 
(Sigma Aldrich, UK). Mobile phase gradient was employed, comprising: buffer A (10mM 
Ammonium Acetate) = 98% and buffer B (acetonitrile) = 2% at 0 min. Buffer A from 98 to 
 30% over 6 minutes and from 30 – 98% over 2 minutes, all at a flow rate of 700 µl/min. 
Eluting compounds of interest were detected using a triple stage quadrupole Vantage mass 
spectrometry system (Thermo Scientific, UK) equipped with heated electrospray (HESI) ion 
source. The ion source conditions for mixed ion mode (positive and negative) HESI analysis 
were as follows: ion spray voltage 3500V, vaporizer temperature 350°C, collision gas (argon) 
1.5 mTorr, sheath and auxiliary gases (nitrogen) were 60 and 20 arbitrary units, respectively. 
The optimum transitional daughter ions mass and collision energy of dFdCTP was m/z –p 
502.0  159.0 (collision energy 37 V).  
 
General Method for the Preparation of phosphorochloridates (3a-l). Anhydrous 
triethylamine (2.0 mol eq.) was added dropwise at -78 ºC to a stirred solution of the appropriate 
aryl dichlorophosphate (1.0 mol eq.) and an appropriate amino acid ester (1.0 mol eq.) in 
anhydrous DCM under argon atmosphere. Following the addition, the reaction mixture was 
allowed to slowly warm to room temperature and stirred for 1-2 hours. A formation of a desired 
compound was monitored by 
31
P NMR. After the reaction was completed, the solvent was 
evaporated under reduced pressure and the resulting residue was re-dissolved in anhydrous Et2O 
and filtered. The filtrate was reduced to dryness to give a crude product as an oil, which was in 
some cases used without further purification in the next step. Most of aryl phosphorochloridates, 
in particular those obtained from the amino acid tosylate salt were purified by flash column 
chromatography using EtOAc/Hexane (7:3) as an eluent.  
Phenyl(isopropoxy-L-alaninyl) phosphorochloridate (3a). Yellowish oil; yield, 80% (2.94 g); 
mixture of diastereoisomers; 
31
P NMR (202 MHz, CDCl3): P 8.08, 7.71 (int. 1.00:1.00). 
1
H 
NMR (500 MHz, CDCl3): H 7.41 – 7.36 (m, 2H, ArH), 7.31 – 7.27 (m, 3H, ArH), 5.21 – 5.01 
(m, 1H, OCH(CH3)2), 4.21 – 4.06 (m, 1H, CHCH3), 1.51 (d, J = 6.9 Hz, 3H, CHCH3), 1.26 – 
1.19 (m, 6H, OCH(CH3)2). 
3-O-(tert-Butoxycarbonyl)-gemcitabine (4) was prepared according to the published 
procedure
28
 and obtained as a white solid. Yield, 75% (1.03 g). 
19
F NMR (470 MHz, MeOD): F  
– 115.74, – 115.75 (d, J = 243 Hz, F), – 119.21 (broad signal, F).  1H NMR (500 MHz, MeOD): 
H 7.68 (d, 1H, J = 7.5, H-6), 6.18 (t, 1H, J = 8.5, H-1), 5.84 (d, 1H, J = 7.5, H-5, 5.13 (q, 1H, J 
= 6.0, H-3), 4.18 – 4.15 (m, 1H, H-4), 3.82 (dd, 1H, J = 13.0, J = 3.0, H-5a), 3.68 (dd, 1H, J = 
13.0, J = 3.0, H-5b), 1.39 (s, 9H, C(CH3)3).  
General Method for the Preparation of Gemcitabine ProTides (5a-l). To a solution of 3-O-
(tert-butoxycarbonyl)-gemcitabine 4 (1.0 eq) in dry THF (10 mL), tert-BuMgCl (1.0 M solution 
in THF, 1.2 eq.) was added in one portion followed by addition of appropriate 
phosphorochloridate (2.0 eq) dissolved in anhydrous THF (3 mL). The reaction mixture was 
stirred for 16 to 18 hours and then evaporated in vacuo to give a crude residue that was purified 
by column chromatography on silica gel, eluting with CH2Cl2-MeOH as a gradient (0% to 5% 
MeOH) to afford the products 5a-l as white solid. 
General Method for the Preparation of Gemcitabine ProTides (6a-l). The 3-O-(tert-
butoxycarbonyloxy)-gemcitabine phosphates (5a-l) were treated with a mixture of TFA/DCM 
(1:1) (6mL) at 0 C. The resulting reaction mixture was stirred at 0 C for 2-4 hours. After the 
reaction was completed the solvents were evaporated and the residue was treated with saturated 
NaHCO3, and extracted with EtOAc. The organic layers were combined, dried (MgSO4), filtered, 
reduced to dryness and purified on silica gel with gradient of eluent MeOH/DCM (2% to 8% 
MeOH). 
2-Deoxy-2,2-difluoro-3-O-(tert-butoxycarbonyloxy)-D-cytidine-5-O-[phenyl (isopropoxy-
L-alaninyl)]phosphate (5a) was obtained from 3-O-(tert-butoxycarbonyl)-gemcitabine 4 (0.25 
g, 0.69 mmol), the phosphorochloridate 3a (0.42 g, 1.37 mmol) and tert-BuMgCl (0.83 mL, 0.83 
mmol) as a white solid. Yield, 83% (0.36 g); mixture of diastereoisomers (45%, 55%). 
31
P NMR 
(202 MHz, MeOD): P 3.86, 3.79.  
1
H NMR (500 MHz, MeOD): H 7.56, 7.48 (2 x d, J = 7.50 
Hz, 1H, H-6), 7.41 – 7.39 (m, 2H, ArH), 7.35 – 7.19 (m, 3H, ArH), 6.30 – 6.28 (m, 1H, H-1), 
5.89, 5.85 (2 x d, J = 7.50 Hz, 1H, H-5), 5.28 – 5.22 (m, 1H, H-3), 5.04 – 4.98 (m, 1H, 
 OCH(CH3)2), 4.54 – 4.50 (m, 1H, H-5a), 4.46 – 4.39 (m, 2H, H-5b, H-4), 4.01 – 3.98 (m, 1H, 
CHCH3), 1.51, 1.50 (2 x s, 9H, C(CH3)3), 1.38 (d, J = 6.30 Hz, 3H, CHCH3). 
 
2-Deoxy-2,2-difluoro-D-cytidine-5-O-[phenyl(isopropoxy-L-alaninyl)] phosphate (6a) was 
obtained from 2-deoxy-2,2-difluoro-3-O-(tert-butoxycarbonyloxy)-D-cytidine-5-O-
[phenyl(isopropoxy-L-alaninyl)]phosphate (5a) (0.36 g, 0.57 mmol) as a white solid. Yield, 50% 
(0.15 g). (ES+) m/z: found: (M + Na
+
) 555.15. C21H27F2N4O8NaP required: (M
+
) 532.43. Mixture 
of diastereoisomers (45%, 55%). 
31
P NMR (202 MHz, MeOD): P 3.80, 3.73. 
19
F NMR (470 
MHz, MeOD): F  – 118.0 (d, J = 240 Hz), – 118.2 (d, J = 240 Hz, F), – 123.43 (– 123.74) 
(broad signal, F).  
1
H NMR (500 MHz, MeOD): H 7.60, 7.55 (2 x d, J  = 7.72 Hz, 1H, H-6), 7.41 
– 7.36 (m, 2H, ArH), 7.29 – 7.22 (m, 3H, ArH), 6.30 – 6.25 (m, 1H, H-1), 5.94, 5.89 (2 x d, J  = 
7.72 Hz, 1H, H-5), 5.03 – 4.97 (m, 1H, OCH(CH3)2), 4.56 – 4.35 (m, 2H, H-5), 4.28 – 4.21 (m, 
1H, H-3), 4.14 – 4.09 (m, 1H, H-4), 3.97 – 3.91 (m, 1H, CHCH3), 1.37 – 1.32 (m, 3H, CHCH3), 
1.25 – 1.22 (m, 6H, OCH(CH3)2). 
13
C NMR (125 MHz, MeOD): C 174.4 (C=O, ester), 167.62 
(C-NH2), 157.80 (C=O base), 152.18, 152.12 (C-Ar), 142.5, 142.41 (CH-base), 130.88 (d, 
3
JC – P 
= 3.75 Hz, CH-Ar), 126.33 (CH-Ar), 122.46 (d, 
1
JC – F = 256 Hz, CF2), 121.42, 121.40 (2 x d, 
3
JC 
– P = 2.5 Hz, CH-Ar), 96.8 (CH-base), 85.6 (broad signal, C-1), 80.40 (C-4), 71.62, 71.20 (2 x d, 
2
JC – F = 37.5 Hz, C-3), 70.24 (OCH(CH3)2), 65.71, 65.66 (2 x d, 
2
JC – P = 5.0 Hz, C-5), 51.89, 
51.75 (CHCH3), 21.99, 21.91, 21.82 (OCH(CH3)2), 16.47 (CHCH3). Reverse HPLC, eluting with 
H2O/MeOH from 100/0 to 0/100 in 40 min., showed two peaks of the diastereoisomers with tR 
22.73 min and tR 23.53 min (44%, 54%).   
 
 
ASSOCIATED CONTENT 
Supporting Information.  Preparative methods, spectroscopic and analytical data for target 
compounds, and xenograft data at low dose. This material is available free of charge via Internet 
at http://pubs.org. 
 
AUTHOR INFORMATION 
Corresponding Author 
*To whom correspondence should be addressed. Phone/fax: +44 2920874537. E-mail: 
mcguigan@cardiff.ac.uk. 
 
ACKNOWLEDGMENT 
We thank Helen Murphy and Lindsey Leven for secretarial assistance and NuCana BioMed Ltd 
and the KU Leuven (GOA 10/014) for financial support. We thank Sofiya Abramchuk and 
Lizette van Berckelaer for excellent laboratory assistance.  
 
ABBREVIATIONS 
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